CVS Caremark CVS unveils its next round of earnings this Thursday, August 4, 2011. Get prepared with Benzinga's ultimate preview for CVS Caremark's second quarter earnings.
Earnings and Revenue:
Analysts are predicting an EPS reading of 64 cents/share and revenues of $26.76 billion. Wall Street will be looking to see how this quarter's numbers compare to the year-ago quarter's positive EPS of 65 cents/share on revenues of $24.01 billion. We'll have to wait for Thursday to see if CVS Caremark reports a decline in EPS and a boost in revenue from the year-ago quarter, as analysts are predicting.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 | Q4 | Q3 | Q2 |
| EPS Estimate | $0.55 | $0.79 | $0.64 | $0.68 |
| EPS Actual | $0.57 | $0.80 | $0.65 | $0.65 |
Stock Performance:
As of July 29, 2011, CVS Caremark's current share price was $36.35. Since January 1st, shares of CVS Caremark have given investors a return of 5.6%. For a full 12 months, the return has risen by 19%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.
- Long-term shareholders are already enjoying 12-month gains prior to the announcement
Average Stock Rating:
The average rating by analysts for CVS Caremark is a Moderate Buy. Over the past three months this rating's strength has declined slightly.
Competitors:
Want to check out the performance of CVS Caremark closest competitors? Take a look at some of the company's peers in the consumer staples sector.
- GNC Holdings GNC: Moderate Buy with a $0.39 recent quarter EPS
- Medco Health Solutions MHS: Hold with a $0.96 recent quarter EPS
- BioScrip (BIOS): Moderate Buy with a $0.07 recent quarter EPS
The retail-drug stores company's industry has seen price/earnings growth of 1.4% during the current fiscal year.
Finally, a description of the company's main areas of operation: CVS Caremark provides prescriptions and related health care services and products.
Take Action:
There is your peek into CVS Caremark's upcoming earnings numbers, including some competitors to watch around the time of the announcement. Check back in with us after the announcement for a full recap of the announcement. In the meantime, here are some links to explore today.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
